A briefing paper on dabigatran and rivaroxaban

Source: London New Drugs Group

Keywords: rivaroxaban, dabigatran, AF, stroke, systemic embolism

Date published: 27/01/2012 14:05

Summary

by: Katie Smith, Ben Rehman

This briefing paper seeks to provide an easily digestible summary of the key issues associated with the new anticoagulants, dabigatran and rivaroxaban, used for the prevention of stroke and systemic embolism in non-valvular AF.

About this library entry

Category: 2.8.2 Oral anticoagulants | Arrhythmias | Drug reviews

NeLM area: Evidence > Drug Specific Reviews

Dabigatran_and_rivaroxaban_briefing_Jan12.pdf

Preview your comment

Add new comment

Comment text:

Comments

There are no comments yet. You could be the first! You must be Logged In to comment.

Printer Friendly Version

Related evidence

2.8.2 Oral anticoagulants

14/02/2012

SMC accepts the use of rivaroxaban (Xarelto™) for the treatment of DVT and the prevention of recurrent DVT and PE following an acute DVT in adults

25/01/2012

NICE issues final guidance on apixaban for the prevention of VTE after total hip or knee replacement in adults

12/12/2011

SMC accepts apixaban (Eliquis®) for VTE prevention following orthopaedic surgery

Arrhythmias

13/10/2011

DTB: Should dabigatran replace warfarin for stroke prevention in AF?

13/09/2011

SMC accepts dabigatran (Pradaxa®) for prevention of stroke and systemic embolism in AF

24/08/2011

Dabigatran etexilate for stroke prevention in patients with atrial fibrillation

Back

Search the NeLM

Medicines A-Z

Preview your comment

Add new comment

Comments